Gsa Capital Partners LLP Scynexis Inc Transaction History

Gsa Capital Partners LLP

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 15, 2024	BUY	$1.4 - $2.77 $26,157 - $51,754	18,684 Added 79.53%	42,177 $84,000
Q1 2024 May 03, 2024	SELL	$1.39 - $2.21 $18,894 - $30,040	-13,593 Reduced 36.65%	23,493 $34,000
Q4 2023 Feb 16, 2024	BUY	$1.56 - $2.24 $30,674 - $44,045	19,663 Added 112.86%	37,086 $82,000
Q3 2023 Nov 15, 2023	BUY	$1.93 - $3.64 $33,626 - $63,419	17,423 New	17,423 $39,000
Q4 2021 Feb 14, 2022	SELL	$4.94 - $7.69 $443,779 - $690,823	-89,834 Closed	0 $0
Q3 2021 Nov 12, 2021	SELL	$5.3 - $7.89 $115,646 - $172,159	-21,820 Reduced 19.54%	89,834 $476,000
Q2 2021 Aug 05, 2021	BUY	$6.5 - $9.97 $509,366 - $781,289	78,364 Added 235.4%	111,654 $822,000
Q1 2021 May 10, 2021	BUY	$6.93 - $9.63 $131,150 - $182,247	18,925 Added 131.74%	33,290 $264,000
Q4 2020 Feb 03, 2021	SELL	$4.28 - $7.87 $29,386 - $54,035	-6,866 Reduced 32.34%	14,365 $110,000
Q3 2020 Nov 06, 2020	BUY	$4.37 - $7.48 $92,779 - $158,807	21,231 New	21,231 $94,000

13.7M

21.9K

2.6K

Ticker SCYX
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 32,651,800
Market Cap $33M
Description
SCYNEXIS, Inc., a biotechnology company, develops products for the treatment fungal infections in the United States. It offers BREXAFEMME (ibrexafungerp tablets) for the treatment of vulvovaginal candidiasis (VVC). The company is developing its lead product candidate, Ibrexafungerp, as a novel oral and intravenous drug for the treatment of vario...

Get notified when there are updates to the investment portfolio of Gsa Capital Partners LLP, based on Form 13F filings with the SEC.

Stay updated on Gsa Capital Partners LLP with notifications on news.